tradingkey.logo
tradingkey.logo
Search

Structure Therapeutics Inc

GPCR
Add to Watchlist
48.040USD
-1.430-2.89%
Close 07-31 16:00ETQuotes delayed by 15 min
3.41BMarket Cap
LossP/E TTM

GPCR Cash Flow Statement

You can access the annual and quarterly cash flow statements of Structure Therapeutics Inc to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q2
FY2022Q1
FY2021Q4
Operating cash flows (indirect method)
Cash flow from continuing operating activities
129.17%15.23M
-76.64%-64.42M
-158.92%-51.00M
-106.71%-54.56M
-53.25%-52.23M
-67.83%-36.47M
4.19%-19.70M
-56.23%-26.39M
-67.82%-34.08M
-80.68%-21.73M
---20.56M
-67.35%-16.89M
-50.23%-20.31M
-11.78%-12.03M
---10.10M
---13.52M
---10.76M
Net income from continuing operations
-62.21%-75.97M
190.47%33.00M
-93.40%-65.71M
-136.85%-61.66M
-79.88%-46.83M
-48.88%-36.48M
-42.39%-33.98M
-11.83%-26.03M
-44.85%-26.04M
-106.34%-24.50M
---23.86M
-66.91%-23.28M
-37.41%-17.98M
11.09%-11.88M
---13.95M
---13.08M
---13.36M
Operating gains losses
110.22%576.00K
50.92%412.00K
34.34%356.00K
25.43%291.00K
23.42%274.00K
279.17%273.00K
235.44%265.00K
213.51%232.00K
217.14%222.00K
0.00%72.00K
--79.00K
25.42%74.00K
0.00%70.00K
9.09%72.00K
--59.00K
--70.00K
--66.00K
Other non-cash items
45.73%-2.60M
67.27%-1.82M
53.64%-2.65M
-37.30%-3.78M
-68.55%-4.79M
-162.54%-5.56M
-312.27%-5.71M
-76.93%-2.75M
-983.59%-2.84M
-426.62%-2.12M
---1.39M
-2020.99%-1.56M
-469.01%-262.00K
-682.61%-402.00K
--81.00K
--71.00K
--69.00K
Change in working capital
1299.24%81.58M
-17471.72%-93.83M
-30.58%9.51M
251.57%3.08M
16.74%-6.80M
-119.63%-534.00K
397.75%13.70M
-132.99%-2.03M
-74.82%-8.17M
712.84%2.72M
--2.75M
100.85%6.17M
-290.15%-4.67M
-129.11%-444.00K
--3.07M
---1.20M
--1.52M
-Change in receivables
--100.00M
---100.00M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
-Change in prepaid expenses
-58.27%-7.99M
-1458.18%-9.13M
-201.87%-2.18M
-102.57%-62.00K
23.83%-5.05M
138.40%672.00K
337.44%2.14M
45.30%2.41M
-117.60%-6.63M
-654.31%-1.75M
---900.00K
285.67%1.66M
-3039.18%-3.04M
-154.95%-232.00K
---893.00K
---97.00K
---91.00K
-Change in other current assets
-388.69%-4.84M
279.11%5.88M
-10025.00%-397.00K
94.04%-106.00K
-49400.00%-990.00K
-46814.29%-3.28M
--4.00K
-2296.30%-1.78M
96.61%-2.00K
88.33%-7.00K
--0.00
--81.00K
---59.00K
-66.67%-60.00K
----
----
---36.00K
-Change in other current liabilities
--206.00K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Cash from non-recurring investing activities
Cash from operating activities
129.17%15.23M
-76.64%-64.42M
-158.92%-51.00M
-106.71%-54.56M
-53.25%-52.23M
-67.83%-36.47M
4.19%-19.70M
-56.23%-26.39M
-67.82%-34.08M
-80.68%-21.73M
---20.56M
-67.35%-16.89M
-50.23%-20.31M
-11.78%-12.03M
---10.10M
---13.52M
---10.76M
Investing cash flow
Net cash from continuing investing activities
276.43%1.18M
-54806.25%-8.75M
129.49%1.57M
-45.67%232.00K
93.83%314.00K
-98.62%16.00K
-16.46%685.00K
123.56%427.00K
--162.00K
1528.17%1.16M
--820.00K
460.38%191.00K
-100.00%0.00
-40.83%71.00K
---53.00K
--65.00K
--120.00K
Capital expenditures
276.43%1.18M
9250.00%1.50M
129.49%1.57M
-45.67%232.00K
93.83%314.00K
-98.62%16.00K
-16.46%685.00K
123.56%427.00K
--162.00K
1528.17%1.16M
--820.00K
--191.00K
-100.00%0.00
-40.83%71.00K
----
--65.00K
--120.00K
Net cash flow from disposal of fixed assets
276.43%1.18M
-54806.25%-8.75M
129.49%1.57M
-45.67%232.00K
93.83%314.00K
-98.62%16.00K
-16.46%685.00K
123.56%427.00K
--162.00K
1528.17%1.16M
--820.00K
460.38%191.00K
-100.00%0.00
-40.83%71.00K
---53.00K
--65.00K
--120.00K
Net cash flow from investment products
-1543.40%-495.76M
58.04%52.55M
71.91%-52.91M
124.09%49.17M
2073.86%34.35M
118.51%33.25M
-708.61%-188.36M
-197.85%-204.09M
103.22%1.58M
-1824.82%-179.59M
--30.95M
-324.88%-68.52M
-23.61%-49.02M
767.67%10.41M
---16.13M
---39.65M
--1.20M
Net cash flow from other investing activities
----
---5.16M
--5.16M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Cash from non-current investing activities
Net cash flow from investing activities
-1560.19%-496.95M
68.93%56.14M
73.91%-49.32M
123.93%48.94M
2300.07%34.03M
118.39%33.23M
-727.45%-189.04M
-197.65%-204.51M
102.89%1.42M
-1847.84%-180.74M
--30.13M
-327.47%-68.71M
-23.41%-49.02M
857.50%10.34M
---16.07M
---39.72M
--1.08M
Financing cash flow
Cash flow from continuous financing activities
-315.33%-1.74M
114532.03%704.99M
7524.44%56.20M
-99.90%517.00K
15.24%809.00K
-99.78%615.00K
-260.04%-757.00K
173400.67%514.70M
-99.59%702.00K
89223.10%281.63M
--473.00K
-100.96%-297.00K
11821.41%169.73M
-174.78%-316.00K
--31.04M
---1.45M
---115.00K
Net cash flow from common stock issuance/repurchase
----
--608.65M
----
----
----
-100.00%0.00
--0.00
--514.57M
----
--300.00M
--0.00
--0.00
--172.30M
----
----
----
----
Net cash flow from preferred stock issuance/repurchase
----
----
----
----
----
----
----
----
----
--0.00
----
----
----
--0.00
--31.50M
----
--0.00
Proceeds from stock option exercised by employees
-9.95%869.00K
483.25%3.59M
-5.04%377.00K
-28.09%517.00K
27.81%965.00K
425.64%615.00K
-16.07%397.00K
301.68%719.00K
2335.48%755.00K
--117.00K
--473.00K
--179.00K
--31.00K
--0.00
----
----
--0.00
Proceeds from issuance of warrants
----
--94.00M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net cash flow from other financing activities
-1573.72%-2.61M
---1.25M
4937.61%55.83M
100.00%0.00
-194.34%-156.00K
100.00%0.00
---1.15M
-23.74%-589.00K
97.96%-53.00K
-5750.63%-18.49M
--0.00
-2.81%-476.00K
-79.63%-2.60M
-174.78%-316.00K
---463.00K
---1.45M
---115.00K
Net cash from non-recurrent financing activities
Net cash from financing activities
-315.33%-1.74M
114532.03%704.99M
7524.44%56.20M
-99.90%517.00K
15.24%809.00K
-99.78%615.00K
-260.04%-757.00K
173400.67%514.70M
-99.59%702.00K
89223.10%281.63M
--473.00K
-100.96%-297.00K
11821.41%169.73M
-174.78%-316.00K
--31.04M
---1.45M
---115.00K
Net cash flow
Beginning cash balance
371.73%799.62M
-40.21%102.91M
-61.47%147.02M
55.49%152.12M
30.60%169.51M
239.94%172.13M
840.18%381.63M
-22.66%97.83M
397.46%129.79M
80.25%50.64M
--40.59M
149.88%126.49M
-75.22%26.09M
-75.59%28.09M
--50.62M
--105.31M
--115.10M
Current period cash flow changes
-2680.55%-483.45M
26692.02%696.71M
78.94%-44.11M
-101.80%-5.10M
45.60%-17.39M
-103.31%-2.62M
-2185.58%-209.50M
430.37%283.80M
-131.83%-31.96M
4055.82%79.16M
--10.04M
-1864.63%-85.90M
283.60%100.40M
79.57%-2.00M
--4.87M
---54.68M
---9.79M
Ending cash balance
107.84%316.17M
371.73%799.62M
-40.21%102.91M
-61.47%147.02M
55.49%152.12M
30.60%169.51M
239.94%172.13M
840.18%381.63M
-22.66%97.83M
397.46%129.79M
--50.64M
-26.85%40.59M
149.88%126.49M
-75.22%26.09M
--55.49M
--50.62M
--105.31M
Free cash flow
126.74%14.05M
-80.66%-65.91M
-157.93%-52.57M
-104.29%-54.79M
-53.45%-52.54M
-59.42%-36.48M
4.66%-20.38M
-56.98%-26.82M
-68.61%-34.24M
-89.18%-22.89M
---21.38M
-69.24%-17.09M
-49.51%-20.31M
-11.20%-12.10M
---10.10M
---13.58M
---10.88M
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

What is operating cash flow?

Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.

How Much Operating Cash Flow Did Structure Therapeutics Inc Generate?

Structure Therapeutics Inc generated -222.20M in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.

How Did Structure Therapeutics Inc's Operating Cash Flow Change Year Over Year?

Structure Therapeutics Inc's operating cash flow increased by -90.51% year over year.

What is investing cash flow?

Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.

How Much Does Structure Therapeutics Inc Spend on Capital Expenditures?

Structure Therapeutics Inc spent 3.61M on capital expenditures in the most recent quarter。

What is financing cash flow?

Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.

How Has Structure Therapeutics Inc's Financing Cash Flow Changed?

Structure Therapeutics Inc used 762.52M in financing activities in the latest quarter.

What is free cash flow and why does it matter for GPCR?

Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.

What was Structure Therapeutics Inc’s free cash flow in the latest quarter?

Free cash flow was -225.81M reflecting a -91.49% change from the previous year.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.